Life Sciences IP Strategy, Patent Strategy, Intellectual Property, Life Sciences IP, Artificial Intelligence, IP Due Diligence & Transactions Xinru Zhang Life Sciences IP Strategy, Patent Strategy, Intellectual Property, Life Sciences IP, Artificial Intelligence, IP Due Diligence & Transactions Xinru Zhang

This Is Where AI Drug Deals Quietly Fall Apart.

AI-enabled drug transactions increasingly turn on more than patents and scientific merit. This article examines data provenance, IP ownership, collaboration terms, and model dependencies that can affect diligence, valuation, and deal readiness.

Read More